<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231103059939N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-24</date_registration>
      <primary_sponsor>Riphah International University Lahore</primary_sponsor>
      <public_title>Athlete's Guide to Faster Recovery: Comparing Muscle Soreness Relief Methods</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of active release and active recovery techniques for delayed onset muscle soreness on recovery and fatigue among athletes.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73608</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple Randomization
each member of the population is assigned a number, after which numbers are selected at random.</study_design>
      <phase>N/A</phase>
      <hc_freetext>DELAYED ONSET MUSCLE SYNDROME.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:22 participants will be randomly allocated in Group A. Rating of fatigue scale, FPT and NPRS will be considered as baseline measure. Active recovery technique will follow the regime of 4 to 12 reps, 1 to 5 sets, at interval of 30 to 40 sec. Intervention 2: Intervention group:22participants will be randomly allocated in Group B. This group will receive active release technique for 15 minutes. ART includes manual therapy to apply compressive, tensile and shear. We will apply deep tension at the area of tenderness whilst the participants will instructed to actively move the DOMS site from a shortened to a lengthened position.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is i have not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sibgha Anum</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Riphah International University, Gulberg campus, 25 Raza Saeed Rd, Bhabra Block M Gulberg III, Lahore, Punjab 25-M Block, Lahore, 54660Lahore , Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 324 6456629</telephone>
        <email>sibghaanum8@gmail.com</email>
        <affiliation>Riphah International University Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sibgha Anum</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Riphah International University,25 Raza Saeed Rd, Bhabra Block M  Punjab 25-M Block, Lahore, 54660 Gulberg campus, Lahore , Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 324 6456629</telephone>
        <email>sibghaanum8@gmail.com</email>
        <affiliation>Riphah International University Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Height range: 165 cm-180 cm
weight range: 60 kg-80 kg;
Healthy
free from cardiovascular diseases, muscle damage and pain, and neurological diseases
Voluntarily participated in the study without any discomfort and sign informed consent
Have past history of DOMS.
Sprinters, runners.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Have had an open wound or inflammatory disease within the last 6 month
Have neurological or muscular disorders that may affect muscle strength
Are with missing limbs
Have a seriously unstable medical condition determined from a physical examination, such as cardiovascular disease, respiratory disease, gastrointestinal disease, hepatobiliary disease, metabolic disease, endocrine disease, renal disease, urinary disease, or problems with the nervous system or mental health
Players who are taking steroids, analgesics, muscle relaxants, or other medications that the researchers decide to be inappropriate, such as antispasmodics, antidepressants, antidiarrheal, antibiotics, or thrombolytic substances.
Have taken other clinical trial drugs for less than 3 months
Have genetic problems, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Are unwilling or unable to follow the study guidelines</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M79.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Myalgia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:22 participants will be randomly allocated in Group A. Rating of fatigue scale, FPT and NPRS will be considered as baseline measure. Active recovery technique will follow the regime of 4 to 12 reps, 1 to 5 sets, at interval of 30 to 40 sec.</i_keyword>
      <i_keyword>Intervention group:22participants will be randomly allocated in Group B. This group will receive active release technique for 15 minutes. ART includes manual therapy to apply compressive, tensile and shear. We will apply deep tension at the area of tenderness whilst the participants will instructed to actively move the DOMS site from a shortened to a lengthened position.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>RECOVERY AMONG ATHLETES. Timepoint: Five readings will be taken. First baseline reading will be taken 24 hours before workout. Pre and post readings of recovery Technique will be taken immediate after workout. Next two readings will be taken after 24 h and 48hours. Method of measurement: Numeric Pain Rating Scale AND Functional Performance Tests:.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>FATIGUE AMONG ATHLETES. Timepoint: Five readings will be taken. First baseline reading will be taken 24 hours before workout. Pre and post readings of recovery Technique will be taken immediate after workout. Next two readings will be taken after 24 h and 48hours. Method of measurement: Rating of fatigue scale AND Likert Scale of Muscle Soreness:.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Riphah International University Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-03</approval_date>
        <contact_name>Research and Ethics committee</contact_name>
        <contact_address>Riphah International University, Gulberg campus, Lahore , Pakistan Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
